Stay updated with breaking news from Development Candidate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company, today released a letter to...
Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of...
KU Leuven enters international licence agreement on cancer therapy These updates are republished press releases and communications from members of the Science|Business Network TEAD inhibition holds great promise as a therapeutic approach as the Hippo pathway is genetically altered in up to 10% of cancers. In mesothelioma, an aggressive and untreatable cancer often caused by asbestos exposure, 60 to 70% of patients have mutations in the Hippo pathway leading to striking sensitivity to TEAD-inhibitors. SpringWorks Expects to Nominate a Development Candidate and Commence IND-E...
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and...